Balda AG has acquired C. Brewer Company
Balda AG (Balda) has acquired C. Brewer Company in Anaheim, California.
The C. Brewer Company, a family-owned business, specializes in precision injection-molded plastics and associated molds, in particular for customers from the medical and optical industries as well as from the automotive and electronics sectors.
Germany-based Balda develops and manufactures high quality plastic systems for medical appliances as well as complete electronic products for communication and entertainment. The Balda Medical segment in Bad Oeynhausen develops and produces plastic solutions for the medical technology, pharmaceutical and diagnosis markets.
This acquisition is part of Balda’s buy-and-build strategy for its medical segment. Through this acquisition, Balda extends its presence in the strategically important US market and particularly strengthens its medical business.
Oaklins' team in Germany advised Balda on this acquisition.
Talk to the deal team
Related deals
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn more